MAP2K7 and melanoma: Furthermore, another single-center, retrospective analysis of 52 patients treated with B-RAF and MEK inhibitors for advanced melanoma over 12 months described disease progression in 59.6% of patients, of whom 70.9% had metastasis in the CNS, and the median time until a relapse was 8 months and the median survival time after progression was 2 months [18].